The stock of Prestige Consumer Healthcare (NYSE:PBH, 30-year Financials) is estimated to be significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $52.2 per share and the market cap of $2.6 billion, Prestige Consumer Healthcare stock gives every indication of being significantly overvalued. GF Value for Prestige Consumer Healthcare is shown in the chart below.
Because Prestige Consumer Healthcare is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth.
Link: These companies may deliever higher future returns at reduced risk.
It is always important to check the financial strength of a company before buying its stock. Investing in companies with poor financial strength have a higher risk of permanent loss. Looking at the cash-to-debt ratio and interest coverage is a great way to understand the financial strength of a company. Prestige Consumer Healthcare has a cash-to-debt ratio of 0.02, which is in the bottom 10% of the companies in Medical Distribution industry. The overall financial strength of Prestige Consumer Healthcare is 3 out of 10, which indicates that the financial strength of Prestige Consumer Healthcare is poor. This is the debt and cash of Prestige Consumer Healthcare over the past years:
It is less risky to invest in profitable companies, especially those with consistent profitability over long term. A company with high profit margins is usually a safer investment than those with low profit margins. Prestige Consumer Healthcare has been profitable 9 over the past 10 years. Over the past twelve months, the company had a revenue of $943.4 million and earnings of $3.25 a share. Its operating margin is 31.53%, which ranks better than 99% of the companies in Medical Distribution industry. Overall, the profitability of Prestige Consumer Healthcare is ranked 7 out of 10, which indicates fair profitability. This is the revenue and net income of Prestige Consumer Healthcare over the past years:
One of the most important factors in the valuation of a company is growth. Long-term stock performance is closely correlated with growth according to GuruFocus research. Companies that grow faster create more value for shareholders, especially if that growth is profitable. The average annual revenue growth of Prestige Consumer Healthcare is -1.4%, which ranks worse than 72% of the companies in Medical Distribution industry. The 3-year average EBITDA growth is 10.7%, which ranks in the middle range of the companies in Medical Distribution industry.
Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, Prestige Consumer Healthcare’s return on invested capital is 7.29, and its cost of capital is 4.56. The historical ROIC vs WACC comparison of Prestige Consumer Healthcare is shown below:
In closing, Prestige Consumer Healthcare (NYSE:PBH, 30-year Financials) stock is believed to be significantly overvalued. The company's financial condition is poor and its profitability is fair. Its growth ranks in the middle range of the companies in Medical Distribution industry. To learn more about Prestige Consumer Healthcare stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
